Peptic ulcer drugs market

Peptic Ulcer Drugs Market, by Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonist, Antibiotics, Ulcer Protective) by Disease Indication (Gastitis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD)), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Request Free Sample

May 2023
CMI3246
204 Pages
Excel & Pdf
Pharmaceutical

Summary

Global Peptic Ulcer Drugs market is estimated to be valued at US$ 34.34 Billion in 2023 and is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030). Increase in product launches by key market players is expected to drive the market growth over the forecast period. Moreover, an increase in government and non-government organizations' initiatives to improve access to affordable vision care and an increase in awareness among people regarding eye-related disease are expected to drive the market growth during the forecast period.

Analysts’ Views on Global Peptic Ulcer Drugs Market:

The global peptic ulcer drugs market growth can be driven by an increase in product launches by key market players. For instance, in November 2021, JB Pharma, a pharmaceutical company, announced the launch of Ranraft for treatment of Gastroesophageal Reflux Disease (GERD).

Figure 1. Global Peptic Ulcer Drugs Market Share (%), by Product Type, 2023

Global Peptic Ulcer Drugs Market- Driver

Increasing prevalence of peptic ulcers

Increasing in the prevalence of peptic ulcer is a major factor boosting growth of the global peptic ulcer drugs market over the forecast period. For instance, data published in April 2021, stated that in the U.S, peptic ulcer disease affects approximately 4.6 million people every year.

Increase in the research and development activities

Increase in the research and development activities by the key players in the market is expected to drive the growth of the market over the forecast period. For instance, on January 4, 2023, Tanta University, based in Egypt, initiated a clinical study titled ‘Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer.’ The study is expected to get completed by June 2025.

Figure 2. Global Peptic Ulcer Drugs Market Share (%), by Region, 2023

Global Peptic Ulcer Drugs Market- Regional Analysis

Among all regions, North America is expected to dominate the global market over the forecast period. This is attributed to North America holding a XX% market share and an increase in product approval by the regulatory bodies in this region. For instance, in June 2022, Zydus Lifesciences, a pharmaceutical company, announced that the company has received approval from the U.S Food and Drug Administration (FDA) to market Famotidine tablets in the strengths of 20 mg and 40 mg. Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid in the stomach.

The European region is expected to be the second-dominating region over the forecast period, due to increase in the adoption of inorganic growth strategies such as acquisition by the key players in the market. For instance, in October 2021, Sandoz, a pharmaceutical company, has announced that the company has completed the acquisition of GSK’s cephalosporin antibiotics. Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum)) in more than 100 markets, further reinforcing its leading global position in antibiotics.

Global Peptic Ulcer Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting the production and demand for drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others faced problems with regard to the transportation of drugs and vaccines from one place to another.

Quarantine, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending. Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources which were required to ensure safety in hospitals and provide treatment to patients with other diseases. This has impacted the overall healthcare market negatively. Additionally, there were delays in hospitalization as the number of patient visits decreased, which is expected to affect the global peptic ulcer drugs market over the forecast period.

Peptic Ulcer Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2022	Market Size in 2023:	US$ 34.34 Bn
Historical Data for:	2017 to 2022	Forecast Period:	2023 to 2030
Forecast Period 2023 to 2030 CAGR:	4.1%	2030 Value Projection:	US$ 45.59 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonist, Antibiotics, Ulcer Protective By Disease Indication: Gastitis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Daewoong Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, GlaxoSmithKline plc.
Growth Drivers:	Increasing prevalence of peptic ulcers An increase in the research and development activities
Restraints & Challenges:	Side effects associated with peptic ulcer drugs

Global Peptic Ulcer Drugs Market Segmentation:

The global peptic ulcer drugs market report is segmented into product type, disease indication and distribution channel.

Based on Product Type, the market is segmented into steroids, proton pump inhibitors, potassium-competitive acid blocker (p-cab), antacids, h2- antagonist, antibiotics and ulcer protective. Out of which, the Proton Pump Inhibitors segment is expected to dominate the golabl peptic ulcer drugs market during the forecast period and this is attributed to an increase in the product launches by key market players. For instance, in March 2021, Xiromed LLC, a U.S.-based generic division of Insud Pharmaceuticals, launched Omeprazole Delayed-Release Capsules, 20mg, generic for Prilose.

Based on Disease Indication, the market is segmented into gastitis, gastric ulcer, duodenal ulcer and gastroesophageal reflux disease (GERD). Out of which, the , duodenal ulcer segment is expected to dominate the global peptic ulcer drugs market during the forecast period and this is attributed to an increase in the global prevalence of gastric ulcer. For instance, data published in April 2021, on Medscape, stated that every year approximately 10% of the U.S. population suffer from duodenal ulcer.

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to an increase in the number of hospital pharmacies. For instance, on September 19, 2022, Apollo Pharmacy, a part of the Apollo Hospitals Group, announced the opening of its 5,000th store in India.

Global Peptic Ulcer Drugs Market Cross Sectional Analysis:

In the product type segment, proton pump inhibitors segment held a dominant position in the Asia Pacific region due to the increasing in adoption of inorganic growth strategies agreements by key market players. For instance, in March 2021, Daiichi Sankyo Co., Ltd., a pharmaceutical company, made an agreement for transferring the marketing and distribution rights for the proton pump inhibitor Nexium capsules 10 mg and 20 mg and Nexium granules for suspension 10 mg and 20 mg (esomeprazole magnesium) to AstraZeneca in Japan.

In disease indication segment, Gastric Ulcer segment held a dominant position in the North America region due to the increasing in research and development activities by key market players. For instance, on June 9, 2020, Spital Limmattal Schlieren, a general and teaching hospital based in Switzerland, initiated a clinical study titled ‘Functional Changes in the Stomach and Esophagus After One Anastomosis Gastric Bypass- OAGB- BiFlux Trial.’ The study is estimated to get completed on May 28, 2028.

Global Peptic Ulcer Drugs Market: Key Developments

In August 2021, the Subject Matter Expert Committee (SEC) functioning under CDSCO recommended Sun Pharma conduct a phase 3 clinical trial of esomeprazole dual-release gastro-resistant tablets 80mg vs esomeprazole gastro-resistant tablets 40mg bids for the proposed indication.

In August 2021, Dr. Reddy's Laboratories, a pharmaceutical company, announced the launch of generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules for the treatment of stomach ulcers, irritable bowel syndrome, and colon inflammation.

In May 2020, researchers from the Michael E. De-Bakey Veterans Affairs Medical Center received U.S. FDA approval for the three drug combination of omeprazole, amoxicillin and rifabutin in one capsule, RHB-105 for treatment of Helicopter pylori infections in adults.

In May 2020, Daewoong Pharmaceutical, a pharmaceutical company, announced for the first time the phase 3 clinical data of Fexuprazan, a novel gastroesophageal reflux disease agent at Digestive Disease Week (DDW) 2020. The abstract of Fexuprazan has been rated in the top 10% posters of all American Gastroenterological Association (AGA) abstracts selected for poster presentation and selected as a Poster of Distinction for presentation during Digestive Disease Week.

In October 2021, RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the granting of U.S. Patent No. 11,135,172 covering Talicia, its U.S. approved medicine indicated for the treatment of H. pylori infection in adults.

Global Peptic Ulcer Drugs Market: Restraint

Side effects associated with peptic ulcer drugs

The major factors that can hamper the growth of the global peptic ulcer drugs market over the forecast period include side effects associated with the drugs used to treat peptic ulcer. Prolonged use of peptic ulcer drugs such as proton pump inhibitors and antibiotics may lead to increased risk of hip bone fracture as the ability to absorb calcium and iron decreases. Other side effects include, risk of opportunistic infections with S. pneumonia and C. defficile, owing to diminished natural gut flora. Such scenario is expected to hamper growth of the global peptic ulcer drugs market.

Global Peptic Ulcer Drugs Market: Key Players

Major players operating in the global peptic ulcer drugs market include Daewoong Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, GlaxoSmithKline plc.

*Definition: Peptic ulcers are open sores that develop on the inside lining of your stomach and the upper portion of your small intestine. The most common symptom of a peptic ulcer is stomach pain. Peptic ulcers include: Gastric ulcers that occur on the inside of the stomach.

Table of Content

Table of Contents

*Browse 25 market data tables and 27 figures on “Global Peptic Ulcer Drugs Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global peptic ulcer drugs market during the forecast period (2023-2030)?

The global peptic ulcer drugs market is estimated to be valued at US$ 34.34 Bn in 2023 and is expected to exhibit a CAGR of 4.1% between 2023 and 2030.

What are the major factors driving the market growth?

Increasing prevalence of peptic ulcers and an increase in the research and development activities by the key players in the market are expected to drive the market growth.

Which is the leading product type segment in the market?

Proton Pump Inhibitors is the leading drug class segment in the market.

What are the key factors hampering the growth of the market?

The major factors that can hamper growth of the market include side effects associated with peptic ulcer drugs.

Which are the major players operating in the market?

Major players operating in the market Daewoong Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, GlaxoSmithKline plc.